Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.6, 2013-06, pp. : 757-760

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of an anti-CD200 antibody for prolonging the survival of allografts: a patent evaluation of WO2012106634A1

By Rygiel Tomasz P Luijk Bart Meyaard Linde

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 3, 2013-03 ,pp. : 389-392

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic compounds: patent evaluation of WO2011011652A1

By Supuran Claudiu T

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 9, 2011-09 ,pp. : 1491-1495

Informa Healthcare

Access to resources Recommend Favorite

Antiobesity carbonic anhydrase inhibitors: a literature and patent review

By Scozzafava Andrea Supuran Claudiu T Carta Fabrizio

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 725-735

Informa Healthcare

Access to resources Recommend Favorite

Antiglaucoma carbonic anhydrase inhibitors: a patent review

By Masini Emanuela

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 705-716

Informa Healthcare

Access to resources Recommend Favorite

Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review

By Aggarwal Mayank Kondeti Bhargav McKenna Robert

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 717-724

Informa Healthcare

Access to resources Recommend Favorite